NodThera to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, today announced that Geoff McDonough, M.D., Chief Executive Officer of NodThera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held February 25-26, 2026, in a virtual format.
NodThera Appoints Geoff McDonough, M.D., as Chief Executive OfficerDr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones
NodThera Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer of NodThera, will present at the 44th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco, CA.
NodThera Appoints Geoff McDonough, M.D., as Independent Board MemberSeasoned physician-executive with global biopharma leadership experience joins Board at a pivotal stage of clinical and corporate development
